This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Mitral Stenosis선천성 승모판협착

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q23.2 | Special Copayment Reduction: V147 (rare disease)
B. SynonymsCongenital mitral stenosis | congenital mitral atresia
C. Adult onsetLikelihood of first onset in adulthood: low — congenital mitral stenosis is mostly diagnosed in infancy to childhood with dyspnea or recurrent pneumonia. Severe cases present with heart failure in infancy, and only some mild cases may first be detected in adulthood.
1. History1902: Enriquez first described congenital mitral stenosis; since the open-heart surgery era, commissurotomy and valve replacement have been applied.
2. CausesVarious anatomic dysplasias, including parachute mitral valve (single papillary muscle), double orifice mitral valve, and supramitral ring.
3. GeneticsAssociated with GATA4, NKX2.5, MYH7, etc.; mostly sporadic; Shone complex involves multiple left heart malformations.
4. General epidemiologyAbout 0.4–0.6% of congenital heart malformations; rare malformation; equal in males and females; more complex course when associated with Shone complex.
5. PathophysiologyMitral inflow obstruction → increased left atrial pressure → pulmonary venous hypertension → pulmonary edema · increased pulmonary vascular resistance.
6. SymptomsFeeding difficulty · tachypnea · recurrent pneumonia in infancy; exercise intolerance · poor growth in childhood; atrial fibrillation · systemic embolism.
7. SignsLow-pitched diastolic rumble (apex), loud S1, opening snap, signs of right ventricular hypertrophy, diastolic thrill.
8. ScreeningNeonatal auscultation and SpO2 screening; fetal echocardiography; evaluation of the entire left heart when Shone complex is suspected.
9. DiagnosisEchocardiography is the standard; Doppler pressure gradient · valve area calculation; CMR for detailed anatomic evaluation; cardiac catheterization for pulmonary artery pressure measurement.
10. TreatmentSurgical valvuloplasty (tailored to anatomic type) is the mainstay; valve replacement delayed as long as possible; supramitral ring is resected.
11. PrognosisIsolated mild cases relatively favorable; parachute type · Shone complex require repeated surgery; progression of pulmonary hypertension is the greatest adverse factor.
12. PreventionPrimary prevention not possible; early diagnosis by fetal echocardiography; complete evaluation for Shone complex; early surgery to prevent pulmonary hypertension.
13. References10 major clinical guidelines and original papers

1. History

Congenital mitral stenosis (CMS) is far rarer than acquired rheumatic mitral stenosis, and historically it took a long time to distinguish the two. Congenitally abnormal mitral valves were described in autopsy records in the late 19th century, but a system for clinically differentiating acquired (rheumatic) from congenital disease was established only in the early 20th century. In 1902, Enriquez first described in detail the anatomic features of congenital mitral stenosis at autopsy.

After Harken, Bailey, and others successfully applied closed commissurotomy to acquired mitral stenosis in 1948, open-heart surgery became possible in the 1950s, and open commissurotomy under direct vision and valvuloplasty began to be performed in patients with congenital mitral stenosis as well. With the introduction of prosthetic valve replacement in the 1960s, valve replacement was performed in patients with severe congenital mitral stenosis in whom repair was not possible.

The anatomic diversity of congenital mitral stenosis (parachute mitral valve, double orifice mitral valve, supramitral ring, papillary muscle abnormalities, etc.) was systematically classified along with advances in echocardiography in the 1970s–80s. In particular, after Shone's complex (the four components of supramitral ring, parachute mitral valve, subaortic stenosis, and coarctation of the aorta) was described by Shone et al. in 1963, the concept of multilevel congenital left heart obstruction was established. Currently in Korea, congenital mitral stenosis is managed within a collaborative care system of pediatric cardiac surgery and adult congenital heart disease specialists.


2. Causes

Congenital mitral stenosis is not due to a single anatomic cause but is a heterogeneous group of disorders in which various developmental abnormalities of the mitral valve cause stenosis. The main causative anatomic types are as follows.

Parachute mitral valve: Normally, two papillary muscles (anteromedial and posterolateral) each support the chordae tendineae, but in the parachute type only a single papillary muscle is present, and all chordae attach to this one papillary muscle. This structure narrows the spaces between the chordae and impedes blood flow. It is one of the most common causes of congenital mitral stenosis.

Double orifice mitral valve: A malformation in which the valve is divided into two orifices by a fibrous bridge, reducing the effective orifice area and causing stenosis. It is often associated with atrioventricular septal defect (AVSD).

Supramitral ring (cor triatriatum sinister): A membrane of fibrous tissue forms within the left atrium, causing obstruction before pulmonary venous return reaches the mitral valve. In severe cases corresponding to the congenital mitral atresia type of Q23.2, the connection between the left atrium and left ventricle may be completely closed.

Shone's complex: A complex malformation in which the four components of supramitral ring, parachute mitral valve, subaortic stenosis, and coarctation of the aorta occur together; it is the representative syndrome of multilevel congenital left heart obstruction.

Genetically, abnormalities of genes such as GATA4, NKX2.5, and MYH7 have been reported, but most cases are sporadic and multifactorial inheritance predominates.


3. Genetics

The genetic basis of congenital mitral stenosis has been less studied than that of bicuspid aortic valve, and most cases occur sporadically. Familial clustering is low, but several genetic abnormalities have been reported.

GATA4(8p23.1): Involved not only in atrial and ventricular septal development but also in formation of the atrioventricular valves (mitral and tricuspid); variants may be accompanied by atrial septal defect together with mitral valve dysplasia. NKX2.5(5q35.1): A regulator of overall cardiac development including mitral valve development; variants cause various cardiac malformations. MYH7(14q11.2): Encodes the β-myosin heavy chain of the myocardium and papillary muscles, and may be associated with papillary muscle abnormalities such as parachute mitral valve.

As an associated chromosomal abnormality, in Down syndrome (trisomy 21) mitral valve abnormalities such as double orifice mitral valve commonly occur together with atrioventricular septal defect. An association of Shone complex with 22q11.2 deletion (DiGeorge/velocardiofacial syndrome) has been reported, but most cases are sporadic.

Currently, the utility of clinical gene panel testing for congenital mitral stenosis is limited; when multiple cardiac malformations are present, chromosomal microarray or whole exome analysis is considered.


4. General epidemiology

Congenital mitral stenosis is a rare malformation, accounting for about 0.4–0.6% of all congenital heart malformations. It is far rarer than acquired (rheumatic) mitral stenosis, and is a rare disease in which substantial experience can be accumulated only at pediatric cardiac specialty centers. The incidence is estimated at about 1 in 40,000–50,000 live births. Incidence in males and females is reported to be equal or with a slight male predominance.

Congenital mitral stenosis is more often accompanied by other left heart malformations (coarctation of the aorta, aortic valve stenosis, VSD, etc.) than it occurs in isolation. Shone complex is the most important pattern of associated malformations; when complex malformations are present, the prognosis is worse than in isolated disease and multistage surgery is required.

Congenital mitral atresia (included in Q23.2) forms part of the spectrum of hypoplastic left heart syndrome (HLHS, Q23.4), in which case single-ventricle palliative surgery (Norwood → Glenn → Fontan) is required.

Independent statistics on prevalence in Korea are scarce, and tracking is carried out through pediatric cardiology joint databases and congenital heart malformation registry data. It is eligible for Special Copayment Reduction registration (V147), and follow-up at a specialty center is recommended.


5. Pathophysiology

The core pathophysiology of congenital mitral stenosis is elevated left atrial pressure and pulmonary venous hypertension due to mitral inflow obstruction.

When the effective mitral valve area decreases, blood flow from the left atrium to the left ventricle is restricted and left atrial pressure rises. Elevated left atrial pressure leads to elevated pulmonary venous and pulmonary capillary wedge pressure (PCWP), resulting in pulmonary edema. When pulmonary venous hypertension persists chronically, structural vascular remodeling of the pulmonary vessels occurs, progressing to pulmonary arterial hypertension.

Because left ventricular filling is reduced, cardiac output falls, and heart rate increases to compensate. In neonates and infants, when this elevated left atrial pressure is superimposed on physiologically high pulmonary vascular resistance, right ventricular afterload also increases markedly.

The mechanisms of stenosis by anatomic subtype include crowding of chordae in the parachute mitral valve narrowing the flow path, direct obstruction of pulmonary venous flow by the membrane in the supramitral ring, and, in the double orifice mitral valve, a combined area of the two small orifices smaller than the area of a normal single orifice.

Elevated left atrial pressure induces atrial fibrillation, and atrial fibrillation in turn increases the risk of left atrial thrombus formation. When thrombi cause systemic embolism, serious complications such as stroke occur.


6. Symptoms

The timing of symptom onset in congenital mitral stenosis varies from the neonatal period to childhood and adolescence, depending on anatomic type and severity of stenosis.

Neonatal and infancy period (severe): Severe dyspnea, tachypnea, chest retractions, and cyanosis appear immediately after birth or within a few weeks. Marked increase in breathing and fatigue during feeding prevent completion of feeds, followed by failure to thrive. Recurrent lower respiratory tract infections (bronchitis, pneumonia) are common. In this period, pulmonary venous hypertension and pulmonary edema are the main problems.

Childhood to adolescence (mild to moderate): Exercise intolerance progresses gradually. Stamina is weaker than in peers and fatigue occurs easily with exercise. Growth may be delayed compared with peers. Palpitations appear when atrial fibrillation develops.

Symptoms of complications: With atrial fibrillation, irregular heartbeat and worsening dyspnea. With systemic embolism after atrial thrombus formation, symptoms such as stroke and limb arterial occlusion. With progression of pulmonary hypertension, exertional syncope and right heart failure (ascites, lower limb edema) appear.

With Shone complex: Coexisting coarctation of the aorta and aortic valve stenosis produce a complex combination of symptoms.


7. Signs

Auscultation findings: The characteristic finding is a low-pitched diastolic rumble heard at the apex, better heard in the left lateral decubitus position. It resembles acquired rheumatic mitral stenosis, but in congenital disease valve pliability may be preserved, so a loud first heart sound (loud S1) and a mitral opening snap may be heard. When severe pulmonary hypertension is present, the pulmonic component (P2) is markedly accentuated and S2 splitting increases.

Diastolic thrill: In severe stenosis, a thrill may be palpable at the apex.

Signs of right ventricular hypertrophy: As pulmonary hypertension progresses, parasternal heave, accentuated pulmonary artery palpation, and chest bulging due to right ventricular hypertrophy appear.

Electrocardiogram: P-wave widening (P mitrale) reflects left atrial enlargement. With pulmonary hypertension, right axis deviation and findings of right ventricular hypertrophy.

Chest X-ray: Left atrial enlargement (double density at the right cardiac border, rightward displacement of the trachea, posterior displacement of the esophagus), pulmonary venous congestion (Kerley B lines, hilar enlargement), and pulmonary artery enlargement in pulmonary hypertension.


8. Screening

Because congenital mitral stenosis is rare, population-wide screening is not performed. The following targeted screening is important.

Neonatal screening: An abnormal heart murmur on auscultation immediately after birth, or pulse oximetry screening (SpO2 <95%), is the first clue. However, in severe congenital mitral stenosis a murmur may be absent or faint initially, so abnormal SpO2 may be more sensitive.

Fetal echocardiography: When a mitral valve abnormality, left atrial enlargement, or reduced left ventricular filling is found on standard prenatal ultrasound, fetal echocardiography is performed. Parachute mitral valve, double orifice mitral valve, and supramitral ring can be diagnosed prenatally.

Shone complex screening: Once congenital mitral stenosis is diagnosed, complete evaluation for associated left heart malformations such as coarctation of the aorta, aortic valve stenosis, and subaortic stenosis is essential. Even if it appears to be a single malformation, the entire left heart inflow and outflow tracts must be evaluated systematically.

Family screening: Familial clustering is rare, but echocardiographic screening may be considered in family members with multiple cardiac malformations.


9. Diagnosis

Echocardiography: The diagnostic standard. Two-dimensional echocardiography evaluates the anatomic type of the mitral valve (parachute, double orifice, supramitral ring), the number and position of papillary muscles, and chordal morphology, and Doppler quantifies the peak and mean diastolic pressure gradients, valve area calculated using the pressure half-time (PHT), and the left atrial–left ventricular pressure gradient. In children, body surface area adjustment is essential. Left ventricular size and function are also evaluated.

Severity criteria for mitral stenosis: a mean diastolic pressure gradient ≥10 mmHg or valve area ≤1.0 cm²/m² BSA is classified as severe, but in children body surface area–adjusted criteria are used.

Transesophageal echocardiography (TEE): Used to evaluate detailed mitral valve anatomy, confirm left atrial thrombus, and plan surgery.

Cardiac MRI (CMR): Useful for three-dimensional evaluation of complex anatomy, left atrial volume, and pulmonary venous anatomy.

Cardiac catheterization: Performed when noninvasive tests alone are insufficient, or during percutaneous balloon valvuloplasty, for direct measurement of left atrial and left ventricular pressures and pulmonary vascular resistance.


10. Treatment

Treatment of congenital mitral stenosis is individualized according to anatomic type and patient age. Percutaneous balloon mitral valvuloplasty (PBMV), the standard in acquired rheumatic mitral stenosis, has limited efficacy in congenital types because of their anatomic characteristics, and surgery is the main treatment.

Indications for intervention: ① Severe stenosis + symptoms (dyspnea, recurrent pneumonia, poor growth) ② Even if asymptomatic, markedly elevated left atrial pressure (PCWP >15 mmHg) or progressive pulmonary hypertension ③ Preventive correction before right ventricular dysfunction

Supramitral ring resection: Resection of the membranous ring is a relatively simple correction that allows immediate pressure relief. However, when abnormalities of the valve itself are present, ring resection alone is insufficient.

Parachute mitral valve repair: Complex reconstructive surgery such as commissurotomy, chordal separation, and chordal shortening or lengthening is required. The goal is to preserve the valve by successful repair, but there is a risk of restenosis.

Double orifice mitral valve: Surgery to merge the two orifices into one by dividing the fibrous bridge is attempted.

Valve replacement: Performed when repair is not possible or has failed. In children it is delayed as long as possible in consideration of growth, and performed after body surface area has become sufficiently large. Mechanical valves are preferred in children in terms of durability but require lifelong anticoagulation.


11. Prognosis

The prognosis of congenital mitral stenosis varies greatly depending on anatomic type, presence of associated malformations, timing of surgery, and degree of pulmonary hypertension.

After supramitral ring resection: For isolated supramitral ring, the prognosis after early surgery is relatively favorable, with 10-year survival of 85–95%. However, when abnormalities of the valve itself are present, the frequency of reoperation increases.

Parachute mitral valve: Even after successful repair, the risk of restenosis is high, so long-term follow-up is essential. The proportion living without reoperation from repair in childhood into adulthood is about 50–60%. Complete correction is difficult because of the structural limitation of a single papillary muscle.

Shone complex: As a multilevel left heart malformation, multiple surgeries are required. A surgical plan spanning stages 1, 2, and 3 is established, and long-term survival is lower than for isolated malformations. Even Shone complex patients who survive into adulthood require repeated intervention and continued follow-up.

Pulmonary hypertension: If pulmonary hypertension has progressed before surgery, pulmonary vascular resistance may not fully normalize even after surgery, and this is one of the most important determinants of long-term prognosis. Early correction is key to preventing pulmonary hypertension.


12. Prevention

Primary prevention of congenital mitral stenosis itself is not possible.

Importance of early diagnosis: Performing surgical correction before pulmonary hypertension progresses is key to improving prognosis. Prenatal diagnosis by fetal echocardiography allows a prompt management plan to be established after birth. Echocardiographic diagnosis immediately after birth and transfer to a specialty center are important.

Complete evaluation for Shone complex: In every patient diagnosed with mitral stenosis, complete evaluation of the entire left heart (mitral valve, subaortic region, aortic valve, aorta) identifies all associated malformations.

Infective endocarditis prophylaxis: Among patients with a dysplastic mitral valve, prophylactic antibiotics are given to high-risk patients before invasive procedures.

Regular follow-up: Even in mild cases, progression of stenosis is followed by echocardiography every 1–2 years. Because changes in relative valve area with growth affect stenosis severity, continuous monitoring is required throughout childhood.

Pregnancy-related prevention: In women with congenital mitral stenosis, pre-pregnancy cardiac evaluation, specialist care during pregnancy, and delivery planning are essential. Pregnancy is very high risk with severe stenosis or pulmonary hypertension.


13. References

  1. Ruckman RN, Van Praagh R. Anatomic types of congenital mitral stenosis: report of 49 autopsy cases with consideration of diagnosis and surgical implications. Am J Cardiol. 1978;42(4):592-601. DOI: 10.1016/0002-9149(78)90953-6. PMID: 696541.

  2. Shone JD, Sellers RD, Anderson RC, et al. The developmental complex of parachute mitral valve, supravalvular ring of left atrium, subaortic stenosis, and coarctation of aorta. Am J Cardiol. 1963;11:714-725. DOI: 10.1016/0002-9149(63)90098-5. PMID: 13986908.

  3. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. DOI: 10.1093/eurheartj/ehaa554. PMID: 32860028.

  4. Oosterhof T, Meijboom FJ, Vliegen HW, et al. Long-term follow-up of corrected congenital heart defects. Int J Cardiol. 2006;113(3):352-358. DOI: 10.1016/j.ijcard.2005.11.022. PMID: 16386800.

  5. Stellin G, Padalino M, Milanesi O, et al. Surgical repair of congenital mitral valve malformations in infancy and childhood. J Heart Valve Dis. 2000;9(5):707-714. PMID: 11041205.

  6. Oppido G, Davies B, McMullan DM, et al. Surgical treatment of congenital mitral valve disease. Ann Thorac Surg. 2008;85(1):S800-S809. DOI: 10.1016/j.athoracsurg.2007.10.063. PMID: 18374004.

  7. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890-1900. DOI: 10.1016/S0735-1097(02)01886-7. PMID: 12084585.

  8. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease. J Am Coll Cardiol. 2008;52(23):e143-e263. DOI: 10.1016/j.jacc.2008.10.001. PMID: 19038677.

  9. Delmo Walter EM, Hetzer R. Surgical management of the congenitally diseased mitral valve in infants and children. Ann Pediatr Cardiol. 2016;9(1):21-33. DOI: 10.4103/0974-2069.171388. PMID: 26957855.

  10. Kalfa D, Butcher J, Bonhoeffer P, Yacoub M. Congenital mitral valve disease: from anatomy to treatment. Prog Pediatr Cardiol. 2012;33(1):45-56. DOI: 10.1016/j.ppedcard.2011.12.007.